Latest Breaking News On - ஜான்சன் நிறுவனம் - Page 14 : comparemela.com
Search jobs Trauma Fixation Devices Market US$ $12.72 Billion Opportunity By 2027
Pune, Maharashtra, India, February 15 2021 (Wiredrelease) Allied Analytics –:According to a new report published by Allied Market Research, titled, “the global internal trauma fixation device market size was valued at $8.80 billion in 2019, and is projected to reach $12.72 billion by 2027, growing at a CAGR of 4.9% from 2020 to 2027.”
Internal Trauma Fixation Device Market by Product (Closure Devices and Bone Cement), Material (Stainless Steel, Nitinol, Titanium, Tritium, and Polyether Ether Ketone), and End User (Hospitals, Orthopedic Surgical Centers, Trauma Centers, and Ambulatory Surgery): Global Opportunity Analysis and Industry Forecast, 2020–2027.
The higher focus on the R&D for hip and knee devices across the globe further intensifies the need for technological development. Moreover, rise in incidence of orthopedic diseases coupled with growing ageing popula
United-states
Portland
Oregon
India
Pune
Maharashtra
America
B-braun-melsungen
Globus-medical-inc
Orthopaedic-implant-company
Orthopedic-surgical-centers
(CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the
Company or
FogChain ) is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the
Definitive Agreement ) with Avisa Pharma Inc. (
Avisa ) and FogChain USA Inc., a wholly-owned subsidiary of FogChain, dated February 1, 2021, in respect of a statutory merger under the Delaware General Corporation Law pursuant to which the Company has agreed to acquire all of the issued and outstanding shares in the capital of Avisa (the
Avisa Shares ), a privately held Delaware company, in exchange for the issuance of approximately 33,263,123 common shares and 14,825,786 restricted voting shares in the capital of the Company (the
New-york
United-states
Sun-mountain
New-mexico
Rocky-mountain
Kellogg-school
California
Texas
Vancouver
British-columbia
Canada
Delaware
5%
Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo.
Germany
Japan
Brazil
China
South-africa
Wuhan
Hubei
Canada
Barcelona
Comunidad-autonoma-de-cataluna
Spain
South-african
vimarsana © 2020. All Rights Reserved.